Oct 21 2010
In the current BioPharma economic climate; with smaller companies desperately needing the right development partners for survival and larger ones needing to support their existing businesses through making the right deals, having the best, most comprehensive, intelligence and insights are absolutely essential for success.
It is into this environment that PharmaTelevision Ltd (a subsidiary of PharmaVentures Ltd), announced today the launch of PharmaDeals(R) v4, the world's first online, multimedia, dedicated pharmaceutical industry deals intelligence resource.
Fintan Walton, PhD, Chief Executive of PharmaVentures says, "There are huge changes taking place in the world of deal making. There are more urgent needs for successful deals to be made and yet the resources required are harder to access. More companies are doing specialist deals, for example, with orphan drugs, and the world is changing as new technologies, mechanisms of action, and even new therapy areas, emerge."
"As leading practitioners of BioPharma deal making, we have worked diligently to develop an intelligence and insight resource that is truly at the cutting edge in terms of its delivery to customers, while we stay very focussed on ensuring quality of the content." Dr Walton continues, "PharmaDeals v4 gives executives within the biopharmaceutical and related industries, an ability to expand their understanding, deduce trends and extract vital intelligence needed for critical decision making, forming a significant part of the solution to help companies navigate these challenging times."
Steve MacKenzie-Lawrie (Director of Sales at PharmaTelevision) explains, "We took the existing PharmaDeals database and have made some truly significant developments. We have provided deeper classifications within drug delivery technologies and orphan drugs and following customer requests, the scope of the PharmaDeals v4 database has been expanded to now include categories of deals that have medical and therapeutic applications in cosmetics, nutritional supplements, packaging, wound care and bioterrorism".
MacKenzie-Lawrie expands, "Business intelligence and BD subscribers asked us to include share-price information, so we now have real-time links to stock markets, including NASDAQ & LSE, providing valuable information on the impact deals have made to the Company's share price."
Also, for the first time, the database now includes exclusive video interviews with deal makers around the world, allowing users to watch the major players in action and so deriving information simply not available elsewhere. This is invaluable in helping to understand and gain further insight into the individuals and companies involved in deal making, after all deal making is a people business.
Dr Walton concludes, "Gaining insight into the companies' deal making activities and the people behind the deals will help our subscribers when they come to negotiate with these individuals across the deal table. Watching the PharmaTelevision interviews is an informative way of doing their due diligence on the companies they want to partner with before they enter into negotiations. This is the icing on the cake."
Combination therapy shows promising results in treating stage 3 melanoma